Drug Science, St. Peters House, 130 Wood Street, London, EC2V 6DL, UK.
Centre for Neuropsychopharmacology, Division of Psychiatry, Department of Brain Sciences, Faculty of Medicine, Imperial College London, London, UK.
Drugs Aging. 2024 Jun;41(6):521-530. doi: 10.1007/s40266-024-01123-y. Epub 2024 Jun 17.
Previous research has suggested that the use of cannabis-based medicinal products is increasing most rapidly among older aged individuals (65+ years). Despite this, little is known about the characteristics of older people using cannabis-based medicinal products and their effectiveness.
We aimed to document the characteristics, outcomes and prescribing patterns of individuals aged 65+ years receiving prescribed cannabis compared to younger individuals receiving prescribed cannabis.
Data from T21, an observational study of patients seeking treatment with medicinal cannabinoids, including self-report ratings of quality of life (assessed via the EQ-5D-5L), general health (assessed via the visual analogue scale of the EQ-5D-5L), mood (assessed via the Patient Health Questionnaire-9) and sleep (assessed using four items derived from the Pittsburgh Sleep Quality Index) were available at treatment entry [n = 4228; 198 (4.7%) 65+ years] and at a 3-month follow-up [n = 2455; 98 (4.2%) = 65+ years].
Relative to younger individuals, those aged over 64 years were more likely to be female (52.5% vs 47.0%; p < 0.001), more likely to report pain as their primary condition (76.3% vs 45.6%; p < 0.001) and less likely to report current daily use (20.2% vs 60.3%, p < 0.001). They received fewer cannabis-based medicinal products (mean = 1.4 vs 2.1; F = 32.3, p < 0.001) and were more likely to receive a prescription for a cannabidiol dominant oil (17.5% vs 5.7%; p < 0.001) and less likely to receive a prescription for delta-9-tetrahydrocannabinol dominant flower (32.5% vs 75.2%; p < 0.001). There were significant improvements across all measures of well-being (p < 0.001), but the extent of improvements in sleep were more marked in younger individuals (p < 0.001).
There are important differences between individuals aged 65+ years and younger individuals receiving cannabis-based medicinal products. Older aged individuals experience considerable improvement in health and well-being when prescribed cannabis-based medicinal products.
先前的研究表明,在老年人群体(65 岁及以上)中,使用大麻类药物的情况增长最快。尽管如此,对于使用大麻类药物的老年人的特征及其有效性,我们知之甚少。
我们旨在记录接受处方大麻类药物治疗的 65 岁及以上人群与接受处方大麻类药物治疗的年轻人群相比的特征、结局和处方模式。
T21 是一项观察性研究,纳入了寻求治疗大麻素的患者,包括使用 EQ-5D-5L 评估的生活质量自评(使用 EQ-5D-5L 视觉模拟量表评估)、一般健康(使用 EQ-5D-5L 视觉模拟量表评估)、情绪(使用患者健康问卷-9 评估)和睡眠(使用源自匹兹堡睡眠质量指数的四个项目评估),这些数据在治疗开始时(n=4228;198(4.7%)65 岁及以上)和 3 个月随访时(n=2455;98(4.2%)=65 岁及以上)可用。
与年轻患者相比,65 岁以上患者更有可能为女性(52.5%比 47.0%;p<0.001),更有可能报告疼痛为主要疾病(76.3%比 45.6%;p<0.001),且更不可能每日使用大麻(20.2%比 60.3%,p<0.001)。他们接受的大麻类药物较少(平均值=1.4 比 2.1;F=32.3,p<0.001),更有可能接受大麻二酚为主的油类药物处方(17.5%比 5.7%;p<0.001),不太可能接受以 delta-9-四氢大麻酚为主的花类药物处方(32.5%比 75.2%;p<0.001)。所有健康指标均有显著改善(p<0.001),但年轻患者的睡眠改善程度更为显著(p<0.001)。
65 岁及以上患者与年轻患者在接受大麻类药物治疗方面存在重要差异。老年患者在接受大麻类药物治疗后,健康和生活质量会有显著改善。